




Instance: composition-en-f40a84cb5d324bdca9e9009c23b60458
InstanceOf: CompositionUvEpi
Title: "Composition for tigecycline Package Leaflet"
Description:  "Composition for tigecycline Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf40a84cb5d324bdca9e9009c23b60458)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tigecycline"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Tigecycline Accord is and what it is used for  </li>
<li>What you need to know before you receive  Tigecycline Accord </li>
<li>How Tigecycline Accord is given </li>
<li>Possible side effects </li>
<li>How to store Tigecycline Accord </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tigecycline is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tigecycline is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tigecycline Accord is an antibiotic of the glycylcycline group that works by stopping the growth of 
bacteria that cause infections. </p>
<p>Your doctor has prescribed Tigecycline Accord because you or your child at least 8 years old has one 
of the following types of serious infections:  </p>
<p>Complicated infection of the skin and soft tissues (the tissue below the skin), excluding diabetic 
foot infections. </p>
<p>Complicated infection in the abdomen. </p>
<p>Tigecycline Accord is only used when your doctor thinks other antibiotics are not suitable. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tigecycline"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tigecycline"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Tigecycline Accord  </p>
<p>If you are allergic to tigecycline, or any of the other ingredients of this medicine (listed in 
section 6). If you are allergic to tetracycline class antibiotics (e.g., minocycline, doxycycline, etc.), you 
may be allergic to tigecycline. </p>
<p>Warnings and precautions </p>
<p>Talk to your doctor or nurse before receiving Tigecycline Accord:  </p>
<p>If you have poor or slow wound healing. </p>
<p>If you are suffering from diarrhoea before you are given Tigecycline Accord. If you develop 
diarrhoea during or after your treatment, tell your doctor at once. Do not take any diarrhoea 
medicine without first checking with your doctor.   </p>
<p>If you have or previously had any side effects due to antibiotics belonging to the tetracycline 
class (e.g., skin sensitization to sun light, staining on developing teeth, pancreas inflammation, 
and alteration of certain laboratory values aimed at measuring how well your blood clots). </p>
<p>If you have, or previously had liver problems. Depending on the condition of your liver, your 
doctor may reduce the dose to avoid potential side effects. </p>
<p>If you have blockage of the bile ducts (cholestasis). </p>
<p>If you suffer from a bleeding disorder or are in treatment with anticoagulant drugs, as this 
medicine can interfere with blood coagulation. </p>
<p>During treatment with Tigecycline Accord: </p>
<p>Tell your doctor immediately if you develop symptoms of an allergic reaction. </p>
<p>Tell your doctor immediately if you develop severe abdominal pain, nausea, and vomiting. 
These may be symptoms of acute pancreatitis (inflamed pancreas which may result in severe 
abdominal pain, nausea, and vomiting). </p>
<p>In certain serious infections, your doctor may consider to use Tigecycline Accord in 
combination with other antibiotics. </p>
<p>Your doctor will monitor you closely for the development of any other bacterial infections. If 
you develop another bacterial infection, your doctor may prescribe a different antibiotic specific 
for the type of infection present. </p>
<p>Although antibiotics including Tigecycline Accord fight certain bacteria, other bacteria and 
fungi may continue to grow. This is called overgrowth. Your doctor will monitor you closely for 
any potential infections and treat you if necessary. </p>
<p>Children 
Tigecycline Accord  is not to be used in children less than 8 years of age due to the lack of data on 
safety and efficacy in this age group and because it may induce permanent dental defects such as 
staining on the developing teeth. </p>
<p>Other medicines and Tigecycline Accord<br />
Tell your doctor if you are taking, have recently taken or might take any other medicines. </p>
<p>Tigecycline Accord may prolong certain tests that measure how well your blood is clotting. It is 
important that you tell your doctor if you are taking medicines to avoid an excess of blood clotting 
(named anticoagulants). If this were the case, your doctor will monitor you closely.  </p>
<p>Tigecycline Accord may interfere with the contraceptive pill (birth control pill). Talk to your doctor 
about the need for an additional method of contraception while receiving Tigecycline Accord.  </p>
<p>Tigecycline Accord may increase the effect of medicines used to suppress the immune system (such as 
tacrolimus or cyclosporine). It is important that you tell your doctor if you are taking these medicines 
so you can be closely monitored. </p>
<p>Pregnancy and breast-feeding 
Tigecycline Accord may cause foetal harm. If you are pregnant or breast-feeding, think you may be 
pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. </p>
<p>It is not known if tigecycline passes into breast milk in humans. Ask your doctor for advice before 
breast-feeding your baby.  </p>
<p>Driving and using machines 
Tigecycline Accord may cause side effects such as dizziness. This may impair your ability to drive or 
operate machinery.  </p>
<p>Tigecycline Accord contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially 'sodium-
free. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tigecycline"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tigecycline"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tigecycline Accord will be given to you by a doctor or a nurse.  </p>
<p>The recommended dose in adults is 100 mg given initially, followed by 50 mg every 12 hours. This 
dose is given intravenously (directly into your blood stream) over a period of 30 to 60 minutes. </p>
<p>The recommended dose in children aged 8 to &lt;12 years is 1.2 mg/kg given every 12 hours 
intravenously to a maximum dose of 50 mg every 12 hours. </p>
<p>The recommended dose in adolescents aged 12 to &lt;18 years is 50 mg given every 12 hours.  </p>
<p>A course of treatment usually lasts for 5 to 14 days. Your doctor will decide how long you should be 
treated. </p>
<p>If you receive more Tigecycline Accord than you should<br />
If you are concerned that you may have been given too much Tigecycline Accord, talk to your doctor 
or nurse immediately. </p>
<p>If you miss a dose of Tigecycline Accord<br />
If you are concerned that you may have missed a dose, talk to your doctor or nurse immediately. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Pseudomembranous colitis may occur with most antibiotics including Tigecycline Accord. This 
consists of severe, persistent or bloody diarrhoea associated with abdominal pain or fever, which can 
be a sign of serious bowel inflammation, which may occur during or after your treatment. </p>
<p>Very common side effects are (may affect more than 1 in 10 people): </p>
<p>Nausea, vomiting, diarrhoea. </p>
<p>Common side effects are (may affect up to 1 in 10 people): </p>
<p>Abscess (collection of pus), infections </p>
<p>Laboratory measurements of decreased ability to form blood clots </p>
<p>Dizziness </p>
<p>Vein irritations from the injection, including pain, inflammation, swelling and clotting </p>
<p>Abdominal pain, dyspepsia (stomach ache and indigestion), anorexia (loss of appetite) </p>
<p>Increases in liver enzymes, hyperbilirubinaemia (excess of bile pigment in the blood) </p>
<p>Pruritus (itching), rash </p>
<p>Poor or slow wound healing </p>
<p>Headache </p>
<p>Increase in amylase, which is an enzyme found in the salivary glands and pancreas, increased 
blood urea nitrogen (BUN). </p>
<p>Pneumonia </p>
<p>Low blood sugar </p>
<p>Sepsis (severe infection in the body and blood stream)/septic shock (serious medical condition 
which can lead to multiple organ failure and death as a result of sepsis) </p>
<p>Injection site reaction (pain, redness, inflammation) </p>
<p>Low protein levels in the blood </p>
<p>Uncommon side effects are (may affect up to 1 in 100 people): </p>
<p>Acute pancreatitis (inflamed pancreas which may result in severe abdominal pain, nausea, and 
vomiting)  </p>
<p>Jaundice (yellow coloration of the skin), inflammation of the liver </p>
<p>Low platelet levels in the blood(which may lead to an increased bleeding tendency and 
bruising/haematoma) </p>
<p>Rare side effects are (may affect up to 1 in 1,000 people): </p>
<p>Low fibrinogen levels in the blood (a protein involved in blood clotting) </p>
<p>Not known side effects are (frequency cannot be estimated from the available data): </p>
<p>Anaphylaxis/anaphylactoid reactions (that may range from mild to severe, including a sudden, 
generalised allergic reaction that may lead to a life-threatening shock [e.g. difficulty in 
breathing, drop of blood pressure, fast pulse]). </p>
<p>Liver failure </p>
<p>Skin rash, which may lead to severe blistering and peeling of the skin (Stevens-Johnson 
Syndrome) </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this 
leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. 
By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tigecycline"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tigecycline"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>This medicinal product does not require any special storage condition. Do not use this medicine after 
the expiry date which is stated on the vial. The expiry date refers to the last day of that month. </p>
<p>Storage after preparation 
Reconstituted solution: Chemical and physical in-use stability has been demonstrated for 6 hours at 
20-25  C. From a microbiological point of view, the product should be used immediately. If not used 
immediately, in-use storage times and conditions prior to use are the responsibility of the user and would 
not be longer than the times stated above for the chemical and physical in-use stability. </p>
<p>Diluted solution: Chemical and physical in-use stability has been demonstrated for 24 hours at 
20-25  C and 48 hours at 2-8  C. From a microbiological point of view, the product should be used 
immediately. If not used immediately, in-use storage times and conditions prior to use are the 
responsibility of the user and would not be longer than the times stated above for the chemical and 
physical in-use stability. </p>
<p>The Tigecycline Accord solution should be yellow to orange in colour after dissolving; if it is not, the 
solution should be discarded. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Tigecycline Accord contains<br />
The active substance is tigecycline. Each vial contains 50 mg of tigecycline. </p>
<p>The other ingredients are maltose monohydrate, hydrochloric acid, and sodium hydroxide. </p>
<p>What Tigecycline Accord looks like and contents of the pack<br />
Tigecycline Accord is supplied as a powder for solution for infusion in a vial and looks like an orange 
powder or cake before it is diluted. These vials are distributed to the hospital in a one vial pack or ten 
vial pack. Not all pack sizes may be marketed.<br />
The powder should be mixed in the vial with a small amount of solution. The vial should be gently 
swirled until the medicine is dissolved. Thereafter, the solution should be immediately withdrawn 
from the vial and added to a 100 ml intravenous bag or other suitable infusion container in the 
hospital.   </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Marketing Authorisation Holder: 
Accord Healthcare S.L.U.<br />
World Trade Center,<br />
Moll de Barcelona, s/n,<br />
Edifici Est 6  planta,<br />
08039 Barcelona, Spain </p>
<p>Manufacturers: 
Accord Healthcare Polska Sp.z o.o. 
ul. Lutomierska 50,<br />
95-200 Pabianice 
Poland </p>
<p>Or 
Laboratori Fundaci  Dau 
C/ C, 12-14 Pol. Ind. 
Zona Franca, Barcelona, 08040,<br />
Spain </p>
<p>This leaflet was last revised in {MM/YYYY}. </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu. </p>
<p>The following information is intended for healthcare professionals only: </p>
<p>Instructions for use and handling (see also 3. How Tigecycline Accord is given in this leaflet) </p>
<p>The powder should be reconstituted with 5.3 ml of sodium chloride 9 mg/ml (0.9 %) solution for 
injection, dextrose 50 mg/ml (5 %) solution for injection, or Lactated Ringer s solution for injection to 
achieve a concentration of 10 mg/ml of tigecycline. The vial should be gently swirled until the active 
substance is dissolved. Thereafter, 5 ml of the reconstituted solution should be immediately withdrawn 
from the vial and added to a 100 ml intravenous bag for infusion or other suitable infusion container 
(e.g. glass bottle). </p>
<p>For a 100 mg dose, reconstitute using two vials into a 100 ml intravenous bag for infusion or other 
suitable infusion container (e.g. glass bottle). </p>
<p>Note: The vial contains a 6 % overage. Thus, 5 ml of reconstituted solution is equivalent to 50 mg of 
the active substance. The reconstituted solution should be yellow to orange in colour; if not, the 
solution should be discarded. Parenteral products should be inspected visually for particulate matter 
and discolouration (e.g. green or black) prior to administration. </p>
<p>Tigecycline should be administered intravenously through a dedicated line or through a Y-site. If the 
same intravenous line is used for sequential infusion of several active substances, the line should be 
flushed before and after infusion of tigecycline with either sodium chloride 9 mg/ml (0.9 %) solution 
for injection or dextrose 50 mg/ml (5 %) solution for injection. Injection should be made with an 
infusion solution compatible with tigecycline and any other medicinal product(s) via this common 
line. </p>
<p>Compatible intravenous solutions include: sodium chloride 9 mg/ml (0.9 %) solution for injection, 
dextrose 50 mg/ml (5 %) solution for injection, and Lactated Ringer s solution for injection. </p>
<p>When administered through a Y-site, compatibility of tigecycline diluted in sodium chloride 0.9 % for 
injection is demonstrated with the following medicinal products or diluents: amikacin, dobutamine, 
dopamine HCl, gentamicin, haloperidol, Lactated Ringer s, lidocaine HCl, metoclopramide, morphine, 
norepinephrine, piperacillin/tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine 
HCl, theophylline, and tobramycin. </p>
<p>Tigecycline Accord must not be mixed with other medicinal products for which compatibility data are 
not available. </p>
<p>Reconstituted solution: Chemical and physical in-use stability has been demonstrated for 6 hours at 
20-25  C. From a microbiological point of view, the product should be used immediately. If not used 
immediately, in-use storage times and conditions prior to use are the responsibility of the user and would 
not be longer than the times stated above for the chemical and physical in-use stability. </p>
<p>Diluted solution: Chemical and physical in-use stability has been demonstrated for 24 hours at 
20-25  C and 48 hours at 2-8  C. From a microbiological point of view, the product should be used 
immediately. If not used immediately, in-use storage times and conditions prior to use are the 
responsibility of the user and would not be longer than the times stated above for the chemical and 
physical in-use stability.  </p>
<p>For single use only, any unused solution should be discarded. </p>         </div>"""      



Instance: composition-da-f40a84cb5d324bdca9e9009c23b60458
InstanceOf: CompositionUvEpi
Title: "Composition for tigecycline Package Leaflet"
Description:  "Composition for tigecycline Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf40a84cb5d324bdca9e9009c23b60458)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - tigecycline"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at bruge Tigecycline Accord 
3. Sådan skal du bruge Tigecycline Accord 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What tigecycline is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What tigecycline is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tigecycline Accord er et antibiotikum tilhørende glycylcyklingruppen, som virker ved at stoppe den 
bakterievækst, der forårsager infektioner. </p>
<p>Din læge har ordineret Tigecycline Accord, fordi du eller dit barn på mindst 8 år har én af følgende 
alvorlige infektioner:</p>
<ul>
<li>Komplicerede infektioner i hud- og bløddele (det væv, som findes under huden) med undtagelse 
af infektioner i fødderne hos personer med sukkersyge. </li>
<li>Komplicerede maveinfektioner </li>
</ul>
<p>Tigecycline Accord anvendes kun, når din læge mener, at andre antibiotika er uegnede. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take tigecycline"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take tigecycline"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lægen kan have foreskrevet anden anvendelse eller dosering end angivet i denne information. Følg 
altid lægens anvisning og oplysningerne på doseringsetiketten.  </p>
<p>Brug ikke Tigecycline Accord 
- Hvis du er allergisk over for tigecyclin eller et af de øvrige indholdsstoffer i Tigecycline Accord 
(angivet i punkt 6).  Hvis du er allergisk over for antibiotika i tetracyklingruppen (f.eks. 
minocyklin, doxycyklin etc.), er du måske allergisk over for tigecyclin. </p>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt lægen eller sygeplejersken, før du bruger Tigecycline Accord:</p>
<ul>
<li>Hvis du har dårlig eller langsom sårheling. </li>
<li>Hvis du lider af diarré, før du får Tigecycline Accord. Hvis du får diarré under eller efter 
behandlingen med Tigecycline Accord, skal du straks kontakte lægen. Du må ikke tage noget 
medicin mod diarré uden først at have rådført dig med lægen.  </li>
</ul>
<p>26
- Hvis du har eller tidligere har haft bivirkninger som følge af antibiotika tilhørende 
tetracyklinklassen (f.eks. øget følsomhed i huden over for sollys, misfarvning under 
tandudviklingen, betændelse i bugspytkirtlen og ændring af visse laboratorieværdier ved måling 
af blodets størkningsevne). 
- Hvis du har eller tidligere har haft leverproblemer. Afhængig af leverens tilstand kan lægen 
eventuelt reducere dosis for at undgå mulige bivirkninger. 
- Hvis du har en blokering af galdegangene (kolestase). 
- Hvis De lider af en blødningsforstyrrelse eller er i behandling med blodfortyndende medicin, 
eftersom dette lægemiddel kan påvirke blodstørkningen. </p>
<p>Under behandling med Tigecycline Accord 
- Fortæl det straks til lægen, hvis du får symptomer på overfølsomhed. 
- Fortæl det straks til lægen, hvis du får stærke mavesmerter, kvalme og opkastning. Det kan være 
symptomer på akut betændelse i bugspytkirtlen. 
- Ved visse alvorlige infektioner kan lægen overveje at bruge Tigecycline Accord i kombination 
med andre antibiotika. 
- Lægen vil overvåge dig nøje for at se, om du udvikler andre infektioner. Hvis du udvikler en 
anden infektion, vil lægen måske ordinere et andet antibiotikum. 
- Selv om antibiotika, herunder Tigecycline Accord, bekæmper visse bakterier, kan andre 
bakterier og svampe fortsætte med at vokse. Dette kaldes overvækst. Lægen vil kontrollere, om 
du har andre infektioner, og behandle dig, hvis det er nødvendigt. </p>
<p>Børn<br />
Børn under 8 år må ikke få Tigecycline Accord, da der mangler data om sikkerhed og virkning hos 
denne aldersgruppe, og fordi det kan medføre permanente skader på tænderne som f.eks. misfarvning 
af tænder under udvikling. </p>
<p>Brug af anden medicin sammen med Tigecycline Accord 
Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger anden medicin, for nylig har brugt 
anden medicin eller planlægger at bruge anden medicin.  </p>
<p>Tigecycline Accord kan påvirke blodets størkningsevne. Det er vigtigt at fortælle det til lægen, hvis du 
tager medicin som hindrer for hurtig størkning af blodet (kaldet antikoagulantia). Hvis du gør det, vil 
lægen undersøge dig omhyggeligt. </p>
<p>Tigecycline Accord påvirker muligvis effekten af p-piller. Tal med lægen om behovet for anden form 
for prævention, mens du får Tigecycline Accord. </p>
<p>Tigecycline Accord kan øge virkningen af lægemidler, der bruges til at undertrykke immunsystemet 
(herunder tacrolimus eller ciclosporin). Det er vigtigt, at De fortæller lægen, hvis De tager disse 
lægemidler, så De kan blive nøje overvåget.  </p>
<p>Graviditet og amning 
Tigecycline Accord forårsager muligvis fosterskader. Hvis du er gravid eller ammer, har mistanke om, 
at du er gravid, eller planlægger at blive gravid, skal du spørge din læge til råds, før du tager dette 
lægemiddel. </p>
<p>Det vides ikke, om tigecycline udskilles i modermælk. Spørg din læge, før du ammer dit barn. </p>
<p>Trafik- og arbejdssikkerhed 
Tigecycline Accord kan forårsage bivirkninger som svimmelhed. Dette kan påvirke din evne til at køre 
bil eller betjene maskiner. </p>
<p>Tigecycline Accord indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. hætteglas og er derfor stort set 
natriumfrit. </p>
<p>27</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take tigecycline"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take tigecycline"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du vil få Tigecycline Accord af en læge eller sygeplejerske. </p>
<p>Den anbefalede startdosis til voksne er 100 mg og derefter 50 mg hver 12. time. Denne dosis gives 
intravenøst (direkte ind i blodåren) over et tidsrum på 30-60 minutter. </p>
<p>Den anbefalede dosis til børn i alderen 8 til &lt;12 år er 1,2 mg/kg, som gives intravenøst hver 12. time 
op til en maksimumdosis på 50 mg hver 12. time. </p>
<p>Den anbefalede dosis til unge i alderen 12 til &lt;18 år er 50 mg hver 12. time.  </p>
<p>En behandling varer almindeligvis 5-14 dage. Lægen vil beslutte, hvor længe du skal behandles. </p>
<p>Hvis du har brugt for meget Tigecycline Accord 
Hvis du tror, at du har fået for meget Tigecycline Accord, skal du straks kontakte lægen eller 
sygeplejersken. </p>
<p>Hvis du har glemt at bruge Tigecycline Accord 
Hvis du tror, at du har glemt at få en dosis, skal du straks kontakte lægen eller sygeplejersken. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Pseudomembranøs kolit kan opstå ved brug af de fleste antibiotika, herunder Tigecycline Accord. Det 
er en tilstand med alvorlig, vedvarende eller blodig diaré ledsaget af mavesmerter eller feber. Det kan 
være tegn på en alvorlig tarmbetændelse, som kan forekomme under eller efter behandlingen. </p>
<p>Meget almindelige bivirkninger: Kan forekomme hos flere end 1 ud af 10 patienter:</p>
<ul>
<li>Kvalme, opkastning, diarré. </li>
</ul>
<p>Almindelige bivirkninger: Kan forekomme hos op til 1 ud af 10 patienter:</p>
<ul>
<li>Bylder, infektioner </li>
<li>Nedsat evne til at få blodet til at størkne (ses ved blodprøver)   </li>
<li>Svimmelhed </li>
<li>Irritation i blodårerne pga. injektionen, inkl. smerte, inflammation, hævelse og størkning </li>
<li>Mavesmerter, dyspepsi (mavegener og fordøjelsesbesvær), appetitløshed </li>
<li>Forhøjede levertal, hyperbilirubinæmi (unormal høj koncentration af galdefarvestof i blodet) </li>
<li>Kløe, udslæt </li>
<li>Dårlig eller langsom sårheling </li>
<li>Hovedpine </li>
<li>Stigning i amylase, som er et enzym, der findes i spytkirtlerne og bugspytkirtlen, forhøjet 
urinkvælstof i blodet </li>
<li>Lungebetændelse </li>
<li>Lavt blodsukker </li>
<li>Blodforgiftning (alvorlig infektion i kroppen og blodbanen), septisk shock (alvorlig tilstand som 
kan føre til svigt af mange organer og død som følge af blodforgiftning) </li>
<li>Reaktioner på injektionsstedet (smerte, rødme, irritation) </li>
<li>Nedsat indhold af protein i blodet. </li>
</ul>
<p>Ikke almindelige bivirkninger: Kan forekomme hos op til 1 ud af 100 patienter:</p>
<ul>
<li>Akut bugspytkirtelbetændelse (betændt bugspytkirtel som kan forårsage svære mavesmerter, 
kvalme og opkastning) </li>
<li>Gulsot (gulfarvning af huden), betændelse i leveren </li>
</ul>
<p>28
- Lavt antal blodplader i blodet (hvilket kan medføre øget tendens til blødning og blå 
mærker/blodansamlinger). </p>
<p>Sjældne bivirkninger er (kan påvirke op til 1 ud af 1.000 personer):</p>
<ul>
<li>Lavt indhold af fibrinogen i blodet (et protein, der medvirker til blodets størkning). </li>
</ul>
<p>Bivirkninger, hvor hyppigheden ikke er kendt:</p>
<ul>
<li>Pludselige overfølsomhedsreaktioner (anafylaktiske/anafylaktoide reaktioner). Disse reaktioner 
kan variere fra milde til alvorlige og kan omfatte en pludseligt opstået overfølsomhedsreaktion i 
hele kroppen, hvilket kan føre til livstruende shock (dvs. besvær med vejrtrækningen, 
blodtryksfald, hurtig puls) </li>
<li>Leversvigt </li>
<li>Udslæt, som kan føre til svær blæredannelse og afskalning af huden (Stevens-Johnsons 
syndrom) </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store tigecycline"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store tigecycline"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. Brug ikke lægemidlet 
efter den udløbsdato (EXP), der står på pakningen. Udløbsdatoen er den sidste dag i den nævnte 
måned. </p>
<p>Opbevaring efter tilberedelse 
Rekonstitueret opløsning: Kemisk og fysisk stabilitet efter åbning er dokumenteret i 6 timer ved 
20-25 °C. Ud fra et mikrobiologisk synspunkt skal præparatet bruges med det samme. Såfremt 
præparatet ikke bruges med det samme, sker opbevaringstider og -betingelser på brugerens eget ansvar 
og må ikke overstige ovenstående angivne tidsrum for kemisk og fysisk stabilitet efter åbning.  </p>
<p>Fortyndet opløsning: Kemisk og fysisk stabilitet efter åbning er dokumenteret i 24 timer ved 20-25 °C 
og 48 timer ved 2-8 °C. Ud fra et mikrobiologisk synspunkt skal præparatet bruges med det samme. 
Såfremt præparatet ikke bruges med det samme, sker opbevaringstider og -betingelser på brugerens 
eget ansvar og må ikke overstige ovenstående angivne tidsrum for kemisk og fysisk stabilitet efter 
åbning. </p>
<p>Tigecycline Accord-infusionsvæsken skal være gul til orange efter opløsning. Hvis det ikke er 
tilfældet, må infusionsvæsken ikke anvendes. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>
<p>29</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tigecycline Accord indeholder </p>
<ul>
<li>Aktivt stof: tigecyclin. Hvert hætteglas indeholder 50 mg tigecyclin. </li>
<li>Øvrige indholdsstoffer: maltosemonohydrat, saltsyre og natriumhydroxid. </li>
</ul>
<p>Udseende og pakningsstørrelse 
Tigecycline Accord leveres som et pulver til infusionsopløsning i et hætteglas og ligner et orange 
pulver eller en orange masse, før det bliver opløst. Disse hætteglas leveres til hospitalet i en pakke 
med 1 hætteglas eller 10 hætteglas. Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Pulveret skal blandes i hætteglasset med en lille smule opløsning. Hætteglasset skal rystes forsigtigt, 
indtil pulveret er opløst. Derefter skal opløsningen straks trækkes op af hætteglasset og overføres til en 
100 ml infusionspose eller anden passende infusionsbeholder på hospitalet. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>Indehaver af markedsføringstilladelsen 
Accord Healthcare S.L.U.<br />
World Trade Center,<br />
Moll de Barcelona, s/n,<br />
Edifici Est 6ª planta,<br />
08039 Barcelona, Spanien </p>
<p>Fremstiller 
Accord Healthcare Polska Sp.z o.o. 
ul. Lutomierska 50,<br />
95-200 Pabianice 
Polen </p>
<p>Eller </p>
<p>Laboratori Fundació Dau 
C/ C, 12-14 Pol. Ind. 
Zona Franca, Barcelona, 08040,<br />
Spanien </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>
<p>30
Nedenstående oplysninger er til læger og sundhedspersonale: </p>
<p>Instruktioner vedrørende anvendelse og håndtering (se også </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-f40a84cb5d324bdca9e9009c23b60458
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tigecycline Package Leaflet for language en"
Description: "ePI document Bundle for tigecycline Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-f40a84cb5d324bdca9e9009c23b60458"
* entry[0].resource = composition-en-f40a84cb5d324bdca9e9009c23b60458

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf40a84cb5d324bdca9e9009c23b60458"
* entry[=].resource = mpf40a84cb5d324bdca9e9009c23b60458
                            
                    
Instance: bundlepackageleaflet-da-f40a84cb5d324bdca9e9009c23b60458
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for tigecycline Package Leaflet for language da"
Description: "ePI document Bundle for tigecycline Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-f40a84cb5d324bdca9e9009c23b60458"
* entry[0].resource = composition-da-f40a84cb5d324bdca9e9009c23b60458

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf40a84cb5d324bdca9e9009c23b60458"
* entry[=].resource = mpf40a84cb5d324bdca9e9009c23b60458
                            
                    



Instance: mpf40a84cb5d324bdca9e9009c23b60458
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Tigecycline Accord 50 mg powder for solution for infusion"
Description: "Tigecycline Accord 50 mg powder for solution for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/19/1394/001  (10 vials)"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Tigecycline Accord 50 mg powder for solution for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: f40a84cb5d324bdca9e9009c23b60458ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "tigecycline"

* status = #current
* mode = #working

* title = "List of all ePIs associated with tigecycline"

* subject = Reference(mpf40a84cb5d324bdca9e9009c23b60458)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#tigecycline "tigecycline"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-f40a84cb5d324bdca9e9009c23b60458) // tigecycline en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-f40a84cb5d324bdca9e9009c23b60458) // tigecycline da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-f40a84cb5d324bdca9e9009c23b60458
InstanceOf: List

* insert f40a84cb5d324bdca9e9009c23b60458ListRuleset
    